About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

One Third of All Cancer Survivors Fail to Have any Conversations with their Healthcare Providers about their Psychosocial Issues

Not terribly surprising, but recent research shows that less than one-third of all cancer survivors of adult cancers in the United States ever had conversations with their healthcare providers about their psychosocial needs. The latest study showing this was published in the Journal of Clinical Oncology.1 This study was a large population-based study of 1777 [...]

Senate Appropriations Subcommittee on Defense Increases FY14 DOD Budget Markup

The US Senate Appropriations Subcommittee on Defense yesterday marked-up their version of the FY14 Defense Appropriations Act. The full committee is scheduled to mark up tomorrow Thursday). The following is an excerpt from the committee’s summary of the bill: Significant increases to DoD medical research efforts, including: o $200 million for the Peer-Reviewed Medical Research [...]

Youtoons Describe Obama Care in a Simple Video

The new Health Care law (Obamacare) is scheduled to take effect in 2014 with the first open enrollment period beginning on October 1, 2013. That is only 2 months away! We all have hear the constant din about the new law, but most of us don't have the slightest understanding of how it will work. [...]

Understanding & Treating Radiation Proctitis Resulting from Prostate Cancer Treatment

One of the more common side effects of primary prostate cancer treatment with any form of x-ray or ionizing radiation is known as radiation proctitis and the related radiation colitis. Radiation proctitis is inflammation and damage to surrounding organs and tissue caused by stray radiation. Radiation proctitis most commonly occurs after treatment for many different [...]

Takeda Un-blinds & Halts the Phase 3 Study of Orteronel in Men with mCRPC That Progressed Post-Chemotherapy

A press release made yesterday brought some bad news to the advanced prostate cancer community. Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has un-blinded and stopped the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed [...]

Go to Top